Neovascular glaucoma
Neovascular glaucoma (NVG) is the presence of new blood vessels on the iris of the affected eye. It was not until the 20th century that knowledge about NVG was established on a sound anatomical basis. In 1906, Coats described the histological findings of new blood vessels on the iris in eyes with central retinal vein occlusion. In 1928, Salus described similar new blood vessels on the iris of diabetic eyes. In the early 20th century, after gonioscopy was introduced into clinical use, Kurz believed that the contraction of connective tissue was the cause of adhesive angle closure. In view of the fact that the cause of this glaucoma is new blood vessels rather than intraocular hemorrhage, Weiss et al. proposed the name of neovascular glaucoma in 1963.
-
Site of disease:
Eye -
Infectious :
Not contagious -
Frequent population:
Newborns -
Related symptoms:
Segmental iris atrophy increased intraocular pressure edema eye pain visual impairment
Related Drugs
Methazolamide Tablets
Indication: It is used as an adjuvant treatment for patients with primary open-angle glaucoma, angle-closure glaucoma and some secondary glaucoma whose intraocular pressure is not well controlled by topical anti-glaucoma drugs. Because this product has less effect on acid-base balance while lowering intraocular pressure, it is better than acetazolamide for patients with severe obstructive pulmonary disease. Methazolamide has less effect on urinary citrate secretion than acetazolamide, so it is recommended for patients who need oral carbonic anhydrase inhibitor treatment but are prone to kidney stone formation.
Manufacturer:
Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd.
Methazolamide Tablets
Indication: It is used as an adjuvant treatment for patients with primary open-angle glaucoma, angle-closure glaucoma and some secondary glaucoma whose intraocular pressure is not well controlled by topical anti-glaucoma drugs. Because this product has less effect on acid-base balance while lowering intraocular pressure, it is better than acetazolamide for patients with severe obstructive pulmonary disease. Methazolamide has less effect on urinary citrate secretion than acetazolamide, so it is recommended for patients who need oral carbonic anhydrase inhibitor treatment but are prone to kidney stone formation.
Manufacturer:
Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd.
Related Ingredients